Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a bowel preparation regimen consisting of polyethylene glycol (PEG) 4000 and simethicone, specifically evaluated for small bowel cleansing in pediatric patients undergoing capsule endoscopy. PEG 4000 acts as an osmotic laxative to clear the bowel of fecal matter by increasing water content in the intestinal lumen, while simethicone serves as an anti-foaming agent to reduce air bubbles that can interfere with endoscopic visualization. The regimen was studied in the PREP-CE trial by Azienda Policlinico Umberto I (Sapienza University of Rome), where it was found to be the most successful preparation regimen, improving visualization particularly in the distal ileum and reducing patient discomfort compared to other cleansing methods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 4000 + simethicone.